Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,802.00
Bid: 1,808.00
Ask: 1,814.00
Change: 48.00 (2.74%)
Spread: 6.00 (0.332%)
Open: 1,740.00
High: 1,830.00
Low: 1,740.00
Prev. Close: 1,754.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CORRECTION: Outcome of IntelliGen Litigation

11 Sep 2019 08:02

RNS Number : 9483L
Genus PLC
11 September 2019
 

This announcement replaces RNS number 9356L issued this morning, removing the word "million" from the number of straws sold by ABS up to 30 June 2019. All other information in the announcement remains unchanged.

 

 

For Immediate Release 11 September 2019

Genus plc

('Genus')

Outcome of latest IntelliGen Litigation

Genus plc (LSE: GNS), a global pioneer in animal genetics, announces that on 10 September 2019 the jury in the US District Court for the Western District of Wisconsin considered damages in the IntelliGen litigation. On 9 September 2019, as previously announced, the jury held that Genus' sexed semen technology, sold by ABS Global, Inc., under the IntelliGen brand, infringed three patents asserted by Inguran, LLC and Cytonome/ST, LLC (collectively "ST").

The jury held that ABS should pay a royalty of $2.60 per straw sold for the infringement of US patents 7,311,476 ("'476") and 7,611,309 ("'309") for 3,295,355 straws sold by ABS up to 30 June 2019. This royalty will be retrospective only, as ABS has already reengineered the IntelliGen technology by incorporating its non-infringing microfluidic chip known as "SSC(B)". ST confirmed in Court that the SSC(B) does not infringe the '476 or '309 patents. The infringement of the US Patent No. 8,206,987 confirms ABS' existing obligation to pay a royalty of $1.25 for each straw of sexed semen produced in the US. 

ABS is considering its options for appeal. 

 

For further information, please contact:

Genus Tel: +44 (0)1256 345970

Stephen Wilson, Group Finance Director

Dan Hartley, Group General Counsel and Company Secretary

Buchanan Tel: +44 (0)207 466 5000

Charles Ryland / Chris lane / Vicky Hayns

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAKNFFSNNEEF
Date   Source Headline
3rd Nov 20227:00 amRNSRuthin Site Visit
14th Oct 202211:39 amRNSTR-1: Notification of Major Holdings
14th Oct 20227:00 amRNSAnnual Report and Annual General Meeting
15th Sep 202210:55 amRNSNotification of Major Holdings
14th Sep 20224:41 pmRNSDirector/PDMR Shareholding
13th Sep 20226:08 pmRNSDirector/PDMR Shareholding
8th Sep 20221:57 pmRNSNotification of Major Holdings
8th Sep 20227:00 amRNSPreliminary Results
2nd Sep 20229:05 amRNSTotal Voting Rights
2nd Aug 20227:00 amRNSAppointment of Joint Corporate Broker
1st Aug 202210:10 amRNSBlock listing Interim Review
21st Jul 202210:21 amBUSForm 8.3 - Genus Plc - CORRECTION
21st Jul 202210:05 amRNSHolding(s) in Company
20th Jul 20223:03 pmRNSNotification of Major Holdings
19th Jul 202211:57 amBUSForm 8.3 - Genus Plc
5th Jul 20222:10 pmRNSNotification of Major Holdings
1st Jul 20229:35 amRNSTotal Voting Rights
24th Jun 20223:42 pmRNSNotification of Major Holdings
6th Jun 20229:11 amRNSNotification of Major Holdings
1st Jun 202212:45 pmRNSNotification of Major Holdings
30th May 202212:18 pmRNSNotification of Major Holdings
17th May 20229:26 amRNSNotification of Major Holdings
21st Apr 20227:00 amRNSNotification of Major Holdings
19th Apr 20221:50 pmRNSNotification of Major Holdings
31st Mar 20221:34 pmRNSDirector Declaration
28th Mar 20225:36 pmRNSNotification of Major Holdings
8th Mar 20223:47 pmRNSNotification of Major Holdings
8th Mar 20221:13 pmRNSNotification of Major Holdings
24th Feb 20227:00 amRNSCollaboration between PIC and Olymel LP in Canada
24th Feb 20227:00 amRNSInterim Results
1st Feb 20224:57 pmRNSBlock listing Interim Review
4th Jan 20229:47 amRNSTotal Voting Rights
26th Nov 202110:18 amRNSDisclosure of Rights Attached to Equity Shares
24th Nov 20215:51 pmRNSDirector/PDMR Shareholding
24th Nov 20212:47 pmRNSResult of AGM
24th Nov 20212:30 pmRNSDirector/PDMR Shareholding
24th Nov 20217:00 amRNSAGM Trading Update
10th Nov 20212:28 pmRNSNotification of Major Holdings
15th Oct 20217:00 amRNSAnnual Report and Annual General Meeting
13th Oct 20215:56 pmRNSDirector/PDMR Shareholding
1st Oct 20213:58 pmRNSTotal Voting Rights
30th Sep 20219:59 amRNSDirector Declaration
29th Sep 20212:59 pmRNSNotification of Major Holdings
15th Sep 20214:45 pmRNSDirector/PDMR Shareholding
14th Sep 20214:32 pmRNSDirector/PDMR Shareholding
9th Sep 20217:00 amRNSPreliminary Results
1st Sep 20212:05 pmRNSTotal Voting Rights
2nd Aug 20214:00 pmRNSBlock listing Interim Review
2nd Aug 202110:09 amRNSTotal Voting Rights
1st Jul 20214:39 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.